Log in

NASDAQ:VXRTVaxart Stock Price, Forecast & News

$2.91
-0.10 (-3.32 %)
(As of 05/22/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.82
Now: $2.91
$3.01
50-Day Range
$1.68
MA: $2.45
$3.66
52-Week Range
$0.25
Now: $2.91
$4.12
Volume4.40 million shs
Average Volume9.13 million shs
Market Capitalization$215.86 million
P/E RatioN/A
Dividend YieldN/A
Beta0.11
Vaxart, Inc., a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Read More
Vaxart logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VXRT
Previous SymbolNASDAQ:NABI
CUSIPN/A
Phone650-550-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.86 million
Book Value$0.42 per share

Profitability

Net Income$-18,650,000.00
Net Margins-252.86%

Miscellaneous

Employees34
Market Cap$215.86 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive VXRT News and Ratings via Email

Sign-up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter.

Vaxart (NASDAQ:VXRT) Frequently Asked Questions

How has Vaxart's stock been impacted by COVID-19 (Coronavirus)?

Vaxart's stock was trading at $2.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VXRT shares have increased by 40.6% and is now trading at $2.91. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Vaxart?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vaxart.

When is Vaxart's next earnings date?

Vaxart is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Vaxart.

How were Vaxart's earnings last quarter?

Vaxart Inc (NASDAQ:VXRT) released its quarterly earnings data on Tuesday, May, 12th. The biotechnology company reported ($0.02) EPS for the quarter, beating the Zacks' consensus estimate of ($0.04) by $0.02. The biotechnology company had revenue of $2.90 million for the quarter, compared to analyst estimates of $2.80 million. Vaxart had a negative return on equity of 94.20% and a negative net margin of 252.86%. View Vaxart's earnings history.

When did Vaxart's stock split? How did Vaxart's stock split work?

Vaxart shares reverse split on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

What price target have analysts set for VXRT?

2 equities research analysts have issued twelve-month target prices for Vaxart's stock. Their forecasts range from $6.00 to $7.00. On average, they expect Vaxart's share price to reach $6.50 in the next year. This suggests a possible upside of 123.4% from the stock's current price. View analysts' price targets for Vaxart.

Has Vaxart been receiving favorable news coverage?

News coverage about VXRT stock has trended somewhat positive recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Vaxart earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutVaxart.

Who are some of Vaxart's key competitors?

What other stocks do shareholders of Vaxart own?

Who are Vaxart's key executives?

Vaxart's management team includes the following people:
  • Dr. Wouter W. Latour M.B.A., M.D., MBA, Pres, CEO, CFO & Director (Age 61)
  • Dr. Sean N. Tucker, Founder & Chief Scientific Officer (Age 51)
  • Mr. John M. Harland M.B.A., CPA, Consultant (Age 67)
  • Ms. Margaret A. Echerd, VP, Corp. Controller & Principal Accounting Officer (Age 60)
  • Mr. Brant Biehn, Sr. VP of Commercial Operations

What is Vaxart's stock symbol?

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Who are Vaxart's major shareholders?

Vaxart's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.73%), Hussman Strategic Advisors Inc. (0.71%), Geode Capital Management LLC (0.48%), Harvest Investment Services LLC (0.07%), Bank of New York Mellon Corp (0.06%) and Strategic Wealth Management Group LLC (0.02%). Company insiders that own Vaxart stock include Armistice Capital Master Fund, Armistice Capital, Llc, John P Richard, Michael J Finney, Sean Tucker, Todd C Davis and Wouter Latour. View institutional ownership trends for Vaxart.

Which major investors are buying Vaxart stock?

VXRT stock was bought by a variety of institutional investors in the last quarter, including Hussman Strategic Advisors Inc., BlackRock Inc., Geode Capital Management LLC, Harvest Investment Services LLC, Bank of New York Mellon Corp, and Strategic Wealth Management Group LLC. Company insiders that have bought Vaxart stock in the last two years include Armistice Capital Master Fund, John P Richard, Michael J Finney, Sean Tucker, and Wouter Latour. View insider buying and selling activity for Vaxart.

How do I buy shares of Vaxart?

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vaxart's stock price today?

One share of VXRT stock can currently be purchased for approximately $2.91.

How big of a company is Vaxart?

Vaxart has a market capitalization of $215.86 million and generates $9.86 million in revenue each year. The biotechnology company earns $-18,650,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Vaxart employs 34 workers across the globe.

What is Vaxart's official website?

The official website for Vaxart is www.vaxart.com.

How can I contact Vaxart?

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.